• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exceptional Response to Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects.

作者信息

Crumbaker Megan, Emmett Louise, Horvath Lisa G, Joshua Anthony M

机构信息

St Vincent's Hospital, Kensington, New South Wales, Australia.

University of New South, Darlinghurst, New South Wales, Australia.

出版信息

JCO Precis Oncol. 2019 Dec;3:1-5. doi: 10.1200/PO.18.00237.

DOI:10.1200/PO.18.00237
PMID:35100671
Abstract
摘要

相似文献

1
Exceptional Response to Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects.镥对存在DNA修复缺陷的前列腺癌中前列腺特异性膜抗原的异常反应。
JCO Precis Oncol. 2019 Dec;3:1-5. doi: 10.1200/PO.18.00237.
2
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.镥-177-前列腺特异性膜抗原放射性核素治疗在转移性去势抵抗性前列腺癌老年患者中的安全性和疗效的回顾性分析。
Oncologist. 2020 Sep;25(9):787-792. doi: 10.1634/theoncologist.2020-0100. Epub 2020 Jun 10.
3
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.分剂量镥-177 标记抗前列腺特异性膜抗原单克隆抗体 J591（Lu-J591）治疗转移性去势抵抗性前列腺癌的 1/2 期研究。
Cancer. 2019 Aug 1;125(15):2561-2569. doi: 10.1002/cncr.32072. Epub 2019 Apr 23.
4
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.镥 177 标记前列腺特异性膜抗原放射性核素肽治疗晚期去势抵抗性前列腺癌的疗效和安全性：常规实践中的疗效和安全性。
Cancer Biother Radiopharm. 2018 Sep;33(7):274-281. doi: 10.1089/cbr.2017.2403. Epub 2018 Jul 10.
5
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ( Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.镥-177 标记抗前列腺特异性膜抗原单克隆抗体 J591（Lu-J591）超分割剂量治疗转移性去势抵抗性前列腺癌的初步研究。
Oncologist. 2020 Jun;25(6):477-e895. doi: 10.1634/theoncologist.2020-0028. Epub 2020 Jan 30.
6
Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.接受镥-177前列腺特异性膜抗原治疗的去势抵抗性前列腺癌患者中前列腺特异性抗原反应的预后重要性。
Q J Nucl Med Mol Imaging. 2021 Sep;65(3):282-286. doi: 10.23736/S1824-4785.19.03165-0. Epub 2019 Oct 9.
7
Radioligand Therapy With 177Lu-Prostate-Specific Membrane Antigen in a Patient With Non-Prostate-Specific Antigen-Secreting Metastatic Prostate Cancer.镥-177 前列腺特异性膜抗原放射性配体疗法治疗非前列腺特异性抗原分泌转移性前列腺癌患者。
Clin Nucl Med. 2020 Oct;45(10):789-791. doi: 10.1097/RLU.0000000000003208.
8
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.镥-PSMA-I&T 放射性配体治疗转移性去势抵抗性前列腺癌的治疗结果、毒性和预测因素。
Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.
9
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记 PSMA 配体治疗转移性去势抵抗性前列腺癌的疗效和生存的真实世界数据分析。
Target Oncol. 2021 May;16(3):369-380. doi: 10.1007/s11523-021-00801-w. Epub 2021 Mar 9.
10
Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.镥-177 标记的抗前列腺特异性膜抗原抗体和配体治疗转移性去势抵抗性前列腺癌：系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):352-360. doi: 10.1038/pcan.2017.23. Epub 2017 Apr 25.

引用本文的文献

1
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.[Lu]Lu-PSMA-617与雄激素受体途径抑制剂对初治转移性去势抵抗性前列腺癌患者疗效对比的3期PSMAfore试验的最终总生存和安全性分析
Ann Oncol. 2025 Jul 16. doi: 10.1016/j.annonc.2025.07.003.
2
Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.Lu-PSMA-617 与改变雄激素受体通路抑制剂治疗用于未经紫杉烷治疗的进展性转移性去势抵抗性前列腺癌患者（PSMAfore）：一项 3 期随机对照试验。
Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15.
3
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to Lu-PSMA-617: A Retrospective Multicenter Cohort Study.前列腺特异性膜抗原表达的基因组相关性及其对 Lu-PSMA-617 的反应：一项回顾性多中心队列研究。
JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634.
4
DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair.放射性药物所致DNA损伤及细胞修复机制
Pharmaceutics. 2023 Dec 12;15(12):2761. doi: 10.3390/pharmaceutics15122761.
5
Radiotheranostics in advanced prostate cancer: Current and future directions.晚期前列腺癌中的放射治疗诊断学：现状与未来方向
Prostate Cancer Prostatic Dis. 2024 Mar;27(1):11-21. doi: 10.1038/s41391-023-00670-6. Epub 2023 Apr 14.
6
Genomic biomarkers to guide precision radiotherapy in prostate cancer.基因组生物标志物指导前列腺癌精准放疗。
Prostate. 2022 Aug;82 Suppl 1(Suppl 1):S73-S85. doi: 10.1002/pros.24373.
7
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.DNA 损伤修复缺陷对转移性去势抵抗性前列腺癌 PSMA 放射性配体治疗反应的影响。
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):71-78. doi: 10.1038/s41391-021-00424-2. Epub 2021 Jul 12.
8
Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review.基因组评估对前列腺癌风险分层、筛查及治疗的临床意义：一项叙述性综述
Prostate Int. 2020 Sep;8(3):99-106. doi: 10.1016/j.prnil.2020.09.001. Epub 2020 Sep 14.
9
Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.通过靶向 PARP 增强 Lu-DOTA-octreotate 放射性核素治疗在生长抑素受体-2 表达肿瘤模型中的抗肿瘤活性。
Sci Rep. 2020 Jun 23;10(1):10196. doi: 10.1038/s41598-020-67199-9.
10
PARP inhibitor combinations in prostate cancer.前列腺癌中的PARP抑制剂联合疗法
Ther Adv Med Oncol. 2020 Mar 18;12:1758835919897537. doi: 10.1177/1758835919897537. eCollection 2020.